We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction (SCENARIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01721538
Recruitment Status : Unknown
Verified November 2012 by Dr. Yaroslav Winter, Philipps University Marburg Medical Center.
Recruitment status was:  Recruiting
First Posted : November 5, 2012
Last Update Posted : November 5, 2012
Von Behring-Röntgen Foundation
Information provided by (Responsible Party):
Dr. Yaroslav Winter, Philipps University Marburg Medical Center

Brief Summary:
SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms. The therapy arm is participating in a comprehensive weight reducing program, whereas the control group takes part in a lecture on healthy nutrition. The primary study objective is to assess the efficacy of non-drug therapeutic weight reduction in the secondary prevention of stroke. Secondary objectives are functional outcome, cognitive status, post stroke depression, and health-related quality of life.

Condition or disease Intervention/treatment
Stroke Obesity Other: Weight reduction program Other: Lecture on healthy nutrition

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Prevention
Official Title: Secondary Prevention of Stroke Through Participation in the Non-drug Therapeutic Weight Reduction Program: A Single-blinded Randomized Controlled Multicenter Trial
Study Start Date : October 2012
Estimated Primary Completion Date : April 2015
Estimated Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Therapy arm
Non-drug therapeutic weight reduction program (15 weeks)
Other: Weight reduction program
Placebo Comparator: Control arm
Lecture on healthy nutrition (1 hour)
Other: Lecture on healthy nutrition

Primary Outcome Measures :
  1. The primary endpoint is the number of deaths or major vascular events defined as stroke, TIA, myocardial infarction or hospitalization due to angina pectoris, which occur between the randomization and last follow-up. [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. Functional outcome [ Time Frame: 18 months ]
    Functional outcome as measured by the modified Rankin Scale (mRS), NIH Stroke Scale (NIHSS) and Barthel Index (BI)

  2. Cognitive deficits [ Time Frame: 18 months ]
    Cognitive deficits in terms of vascular dementia as measured by the Structural Interview for diagnosis of Alzheimer dementia and multi-infarct dementia (SIDAM), the Vascular Dementia Assessment Scale cognitive subscale (VADAS-Cog), Stroop test and the Trail Makin Test

  3. Post stroke depression [ Time Frame: 18 months ]
    Post stroke depression as measured by Beck Depression Inventar (BDI II) and health-related quality of life (HrQoL) as measured by the EuroQol (EQ5D, visual analogue scale), Stroke Specific Quality of Life Scale, Stroke Impact Scale.

  4. Severity of arterial hypertension, diabetes mellitus and hyperlipidemia [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of ischemic stroke
  • Age: 20 - 85 years
  • BMI ≥ 25.0 kg/m² or waist circumference in men ≥ 94cm and in women ≥ 80cm
  • Functional impairment, which would allow to participate in weight reduction program (mRS 0-4, NIHSS 0-12)
  • Patient must be capable of understanding informed consent
  • Written informed consent for participation in the study

Exclusion Criteria:

  • Intracerebral hemorrhage as primary cause of stroke (secondary hemorrhage is not an exclusion criterion)
  • Speech disturbance (aphasia or sever dysarthria)
  • Dimming of consciousness
  • Stroke due to arterial dissection or coagulation disorder
  • Drug-related weight changes during previous 3 months
  • Changes in appetite influencing medication listed in appendix during previous 3 months
  • Bariatric surgery in the past
  • Diabetes mellitus with a history of severe ketoacidosis
  • Pregnancy or nursing
  • Severe co-morbid disorders, e.g.:

    • AV-Block ≥ 2nd degree
    • Heart insufficiency (NYHA > 2)
    • Pericarditis, pericardial effusion
    • Severe kidney insufficiency (Creatinine > 3 mg/dl; Urea > 150 mg/dl)
    • Hepatic insufficiency (GOT > 3 x ULN; GPT > 3 x ULN)
    • Severe psychiatric disease within the last six months (psychosis, suicide attempts)
    • Chronic alcohol addiction or drug addiction
    • HIV- or hepatitis infection
    • Bleeding peptic ulcer (unless there is radiological evidence of healing 6 months prior to start of obesity program)
  • Cognitive impairment with MMSE < 20
  • Depression with BDI > 20
  • Patients who are unable to give consent to study participation (MMSE < 20, aphasia)
  • Recurrent stroke or myocardial infarction in the period between screening for study participation and start of weight reduction program
  • Simultaneous participation in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01721538

Contact: Yaroslav Winter, MD 00496421-5865200 wintery@med.uni-marburg.de

Department of Neurology, Philipps-University Marburg Recruiting
Marburg, Germany
Contact: Winter Yaroslav, MD    004964215865200    wintery@med.uni-marburg.de   
Principal Investigator: Yaroslav Winter, MD         
Sponsors and Collaborators
Philipps University Marburg Medical Center
Von Behring-Röntgen Foundation

Responsible Party: Dr. Yaroslav Winter, Neurologist and Research Fellow, Philipps University Marburg Medical Center
ClinicalTrials.gov Identifier: NCT01721538     History of Changes
Other Study ID Numbers: SCENARIO OP1
First Posted: November 5, 2012    Key Record Dates
Last Update Posted: November 5, 2012
Last Verified: November 2012

Keywords provided by Dr. Yaroslav Winter, Philipps University Marburg Medical Center:
weight reduction

Additional relevant MeSH terms:
Weight Loss
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Body Weight Changes
Body Weight
Signs and Symptoms